Navigation Links
Data from Clinical Studies of bioTheranostics' CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
Date:6/7/2011

SAN DIEGO, June 7, 2011 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from clinical studies utilizing the company's CancerTYPE ID®, and Breast Cancer Index(SM). Data from the studies were presented this week at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

On June 6, scientists from bioTheranostics and the Institut Gustave-Roussy (France) presented results from a study evaluating the utility of the Breast Cancer Index(SM) (BCI) for predicting pathologic complete response (pCR) in breast cancer patients treated with neoadjuvant chemotherapy.  In the study, patients with a high BCI score had a more favorable response to standard chemotherapies such as anthracycline and taxane (P=0.02).

"Patients determined as high-risk by BCI had a 10-fold greater probability of pCR with the chemotherapy regimen when compared to the low risk patients," said Mark Erlander, Ph.D., chief scientific officer, bioTheranostics. "These results suggest that BCI is predictive of chemotherapy response."

bioTheranostics also presented diagnostic utility data for CancerTYPE ID® from a study of 754 metastatic cancer cases.  The results showed that pre-CancerTYPE ID® pathological workup involved a mean of seven immunohistochemistry (IHC) stains to identify the cancer site of origin.  Increasing the number of IHC stains beyond seven lengthened the diagnostic process without improving the accuracy of the final result.

"Quickly and accurately diagnosing the site of origin is critical in the care of metastatic cancer patients," said Richard Ding, chief executive officer, bioTheranostics.  "This study illustrated that the current diagnostic process is not standardized and often time- consuming."  In the study, CancerTYPE ID required only five days of lab processing to predict a single primary site in more than 90 percent of the cases, and provided a more objective and informative diagnosis to physicians.

Finally, in collaboration with a group of international clinicians, bioTheranostics presented data from a study evaluating the utility of a novel P95 assay. The study assessed the assay's ability to identify the truncated form of the Her2 gene in Her2-positive breast cancer patients as a means to predict trastuzumab response.

About bioTheranostics

Advancing Molecular Diagnostics in Oncology

bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index(SM), which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; and the CancerTYPE ID® test, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin. For more information call 1-858-587-5870 or visit www.bioTheranostics.com.

About bioMerieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France.

bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in
agri-food, pharmaceutical and cosmetic products.

bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).

Other information can be found at www.biomerieux.com

bioTheranostics Contacts

Tim Schofield
Tel: + 1 858 587 5890
tim.schofield@biotheranostics.com

Michele Parisi
Tel: + 1 925 864 5028
mparisi@biocommnetwork.com

bioMerieux Contact

Koren Wolman-Tardy
Tel: + 011 33 6 13 94 51 14
media@eu.biomerieux.com


'/>"/>
SOURCE bioTheranostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tocagens First-in-Human Clinical Trial of Toca 511 Enrolling Patients with High Grade Glioma
2. Precision Therapeutics Presents Clinical Study Emphasizing the Role of ChemoFx® in Directing Chemotherapy in Gynecological Cancers
3. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
4. NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
5. Late-Breaking ASCO Data Demonstrate Circulating Tumor Cells as Potential Biomarker for Metastatic Prostate Cancer Clinical Trials
6. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
7. Spherix Drug Candidate SPX-106 Shows Statistically Significant Reductions in Serum Triglycerides in Preclinical Testing
8. IDEV Technologies Announces Completion of SUPERB Clinical Trial Enrollment
9. Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
10. PLC Ramps Up for U.S. Clinical Trial of RenalGuard®
11. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
(Date:4/28/2016)... WARSAW, Ind., April 28, 2016 , Net ... a reported basis over the prior year period, and an ... basis , Diluted EPS for the first quarter were ... period, and $2.00 adjusted, an increase of 29.9% over the ... revenue and adjusted earnings guidance for 2016 Zimmer ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... Since launching ... national charitable foundation serving the footwear industry, has broken all previous participation records ... 130 companies across 23 states during the months of April and May, the ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce is on ... security. Most importantly, employees are the single most important asset in creating value ... unhappy? , Just under half of American workers are emotionally checked out with ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... that infants born with severe congenital diaphragmatic hernia have better survival rates if ... congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, letting ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free Certification Program ... to announce the launch of the GFCP Scoop in response to ... purpose of the GFCP Scoop site is to keep the gluten-free ...
(Date:4/29/2016)... ... April 29, 2016 , ... For those who skip ... meal to miss. That was among the many new lifestyle diet tips offered by ... Sharon Kleyne Hour® Power of Water® radio show. Bonny and Lawrence noted that because ...
Breaking Medicine News(10 mins):